Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Rank and Stock Performance - The Zacks Rank system has a strong track record, with 1 stocks generating an average annual return of +25% since 1988 [1] - Pfizer currently holds a Zacks Rank of 2 (Buy) [1] - Pfizer's stock closed at $26 56, marking a -0 67% move from the previous day, underperforming the S&P 500's daily loss of 0 04% [2] - Over the past month, Pfizer's shares appreciated by 3 52%, outperforming the Medical sector's loss of 4 31% and the S&P 500's gain of 1 05% [2] Earnings and Revenue Projections - Pfizer's upcoming earnings per share (EPS) are projected to be$ 0 48, reflecting a 380% increase from the same quarter last year [3] - Revenue for the upcoming quarter is anticipated to be $17 48 billion, indicating a 22 67% upward movement from the same quarter last year [3] - For the full year, earnings are projected at$ 2 91 per share, representing a +58 15% change from the prior year [4] - Full-year revenue is estimated at $63 34 billion, reflecting an +8 28% change from the prior year [4] Valuation Metrics - Pfizer is currently traded at a Forward P/E ratio of 9 18, marking a discount compared to its industry's average Forward P/E of 13 9 [9] - Pfizer has a PEG ratio of 0 65, significantly lower than the Large Cap Pharmaceuticals industry average PEG ratio of 1 46 [11] Industry and Analyst Insights - The Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 136, placing it in the bottom 46% of all 250+ industries [10] - Analyst estimate revisions for Pfizer reflect the latest short-term business trends and can indicate confidence in the company's performance [5] - Research shows that estimate alterations are directly linked with near-future stock price performance [6]